Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:CNTB NASDAQ:KYTX NASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.28+0.4%$2.42$0.86▼$4.46$555.73M0.4617.68 million shs4.47 million shsCNTBConnect Biopharma$2.36+1.3%$2.74$0.70▼$3.82$131.70M-0.21231,738 shs95,044 shsKYTXKyverna Therapeutics$9.35+0.5%$8.82$2.05▼$13.67$562.93M2.051.25 million shs458,952 shsSTROSutro Biopharma$40.24+1.0%$26.90$6.74▼$41.88$659.90M1.63267,329 shs236,907 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-1.73%+6.57%-13.36%+34.32%+89.96%CNTBConnect Biopharma-6.05%-5.67%-17.38%-4.12%+191.25%KYTXKyverna Therapeutics-1.80%+5.68%-0.32%+17.28%+360.40%STROSutro Biopharma+5.68%+8.77%+54.92%+156.64%+300.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.28+0.4%$2.42$0.86▼$4.46$555.73M0.4617.68 million shs4.47 million shsCNTBConnect Biopharma$2.36+1.3%$2.74$0.70▼$3.82$131.70M-0.21231,738 shs95,044 shsKYTXKyverna Therapeutics$9.35+0.5%$8.82$2.05▼$13.67$562.93M2.051.25 million shs458,952 shsSTROSutro Biopharma$40.24+1.0%$26.90$6.74▼$41.88$659.90M1.63267,329 shs236,907 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-1.73%+6.57%-13.36%+34.32%+89.96%CNTBConnect Biopharma-6.05%-5.67%-17.38%-4.12%+191.25%KYTXKyverna Therapeutics-1.80%+5.68%-0.32%+17.28%+360.40%STROSutro Biopharma+5.68%+8.77%+54.92%+156.64%+300.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.73Moderate Buy$8.44270.11% UpsideCNTBConnect Biopharma 2.80Moderate Buy$8.67267.23% UpsideKYTXKyverna Therapeutics 2.60Moderate Buy$28.67206.60% UpsideSTROSutro Biopharma 2.85Moderate Buy$40.781.34% UpsideCurrent Analyst Ratings BreakdownLatest CNTB, ALLO, STRO, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026CNTBConnect Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/4/2026STROSutro Biopharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/1/2026ALLOAllogene Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/1/2026STROSutro Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026STROSutro Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$50.004/30/2026STROSutro Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$50.004/23/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.004/23/2026STROSutro Biopharma Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$35.00 ➝ $41.004/17/2026STROSutro Biopharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/17/2026STROSutro Biopharma Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$23.00 ➝ $35.004/16/2026ALLOAllogene Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K27,909.48N/AN/A$1.30 per share1.75CNTBConnect Biopharma$60K2,223.12N/AN/A$0.75 per share3.15KYTXKyverna TherapeuticsN/AN/AN/AN/A$3.85 per shareN/ASTROSutro Biopharma$102.48M6.51N/AN/A($15.43) per share-2.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.87N/AN/AN/AN/A-57.07%-41.63%5/12/2026 (Estimated)CNTBConnect Biopharma-$55.48M-$1.00N/AN/AN/AN/A-88.21%-74.26%5/21/2026 (Estimated)KYTXKyverna Therapeutics-$161.31M-$3.65N/AN/AN/AN/A-81.47%-66.70%5/12/2026 (Estimated)STROSutro Biopharma-$191.09M-$26.10N/AN/AN/A-186.45%N/A-79.02%5/14/2026 (Estimated)Latest CNTB, ALLO, STRO, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026CNTBConnect Biopharma-$0.29N/AN/AN/AN/AN/A5/14/2026Q1 2026STROSutro Biopharma-$2.7363N/AN/AN/A$8.89 millionN/A5/12/2026Q1 2026ALLOAllogene Therapeutics-$0.19N/AN/AN/A$0.00 millionN/A5/12/2026Q1 2026KYTXKyverna Therapeutics-$0.75N/AN/AN/AN/AN/A3/31/2026Q4 2025CNTBConnect Biopharma-$0.30-$0.27+$0.03-$0.27$0.00 million($0.05) million3/26/2026Q4 2025KYTXKyverna Therapeutics-$0.80-$0.80N/A-$0.80N/AN/A3/12/2026Q4 2025ALLOAllogene Therapeutics-$0.25-$0.17+$0.08-$0.17$0.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A7.937.93CNTBConnect Biopharma0.013.743.74KYTXKyverna Therapeutics0.117.757.75STROSutro BiopharmaN/A2.012.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%CNTBConnect Biopharma58.72%KYTXKyverna Therapeutics18.08%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%CNTBConnect Biopharma22.60%KYTXKyverna Therapeutics17.60%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310244.82 million212.50 millionOptionableCNTBConnect Biopharma11056.52 million43.75 millionOptionableKYTXKyverna Therapeutics9660.53 million49.88 millionOptionableSTROSutro Biopharma24016.57 million15.97 millionOptionableCNTB, ALLO, STRO, and KYTX HeadlinesRecent News About These CompaniesSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 7 at 3:48 AM | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Moderate Buy" by AnalystsMay 7 at 3:06 AM | marketbeat.comSutro Biopharma (STRO) Expected to Announce Earnings on ThursdayMay 7 at 3:06 AM | americanbankingnews.comSutro Biopharma (STRO) to Release Earnings on ThursdayMay 7 at 3:03 AM | marketbeat.comSutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Truist FinancialMay 6 at 6:24 AM | marketbeat.comSutro Biopharma (NASDAQ:STRO) Sets New 1-Year High - Still a Buy?May 5 at 3:39 PM | marketbeat.comLifesci Capital Forecasts Sutro Biopharma Q1 EarningsMay 5 at 8:32 AM | marketbeat.comSutro Biopharma (NASDAQ:STRO) Upgraded at Lifesci CapitalMay 2, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Upgraded by Mizuho to "Strong-Buy" RatingMay 1, 2026 | marketbeat.comCitizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead ProgramMay 1, 2026 | insidermonkey.comMizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendationMay 1, 2026 | msn.comSutro Biopharma: Recycling Past Data Ahead Of The Readout, SellMay 1, 2026 | seekingalpha.comShort Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Grows By 17.0%April 30, 2026 | marketbeat.comHere is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right NowApril 29, 2026 | finance.yahoo.comSutro Biopharma (NASDAQ:STRO) Hits New 1-Year High - What's Next?April 29, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Shares Up 5.6% - What's Next?April 28, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Shares Gap Down - What's Next?April 27, 2026 | marketbeat.comSutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - SlideshowApril 24, 2026 | seekingalpha.comSutro Biopharma (NASDAQ:STRO) Shares Down 6.1% - Time to Sell?April 24, 2026 | marketbeat.comCitizens Jmp Boosts Sutro Biopharma (NASDAQ:STRO) Price Target to $41.00April 23, 2026 | marketbeat.comSutro Biopharma (NASDAQ:STRO) Reaches New 1-Year High - Still a Buy?April 21, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026A Quiet Outperformer With a Catastrophe CaveatBy Peter Frank | April 14, 2026The Market Is Selling Everything, but These 5 Stocks Aren't Breaking DownBy Bridget Bennett | April 10, 2026Lumentum's 1,500% Run and Nvidia's $2 Billion Deal: What Comes Next?By Chris Markoch | April 9, 2026Levi Strauss Gains as DTC Continues to Fuel Revenue GrowthBy Chris Markoch | April 10, 2026CNTB, ALLO, STRO, and KYTX Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$2.28 +0.01 (+0.44%) Closing price 04:00 PM EasternExtended Trading$2.31 +0.03 (+1.14%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Connect Biopharma NASDAQ:CNTB$2.36 +0.03 (+1.29%) Closing price 04:00 PM EasternExtended Trading$2.37 +0.01 (+0.21%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Kyverna Therapeutics NASDAQ:KYTX$9.35 +0.05 (+0.54%) Closing price 04:00 PM EasternExtended Trading$9.35 0.00 (0.00%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Sutro Biopharma NASDAQ:STRO$40.24 +0.41 (+1.03%) Closing price 04:00 PM EasternExtended Trading$41.05 +0.81 (+2.01%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
